The combination of DNA hypomethylating agents 5-aza-2’-dexoxydytidine (DAC) with BMN-673 (the PARPi talazoparib) increases cytotoxicity in SETD2-deficient ccRCC cell lines (111). The gene discussed is SETD2; the disease is nonpapillary renal cell carcinoma.